144 related articles for article (PubMed ID: 29538006)
1. Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Ito Y; Noguchi K; Morishima Y; Yamaguchi K
Blood Coagul Fibrinolysis; 2018 Apr; 29(3):314-321. PubMed ID: 29538006
[TBL] [Abstract][Full Text] [Related]
2. Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
Bird E; Tamura J; Bostwick JS; Steinbacher TE; Stewart A; Liu Y; Baumann J; Feyen J; Tamasi J; Schumacher WA
Thromb Res; 2007; 120(4):549-58. PubMed ID: 17229457
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
4. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
5. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
[TBL] [Abstract][Full Text] [Related]
6. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
[TBL] [Abstract][Full Text] [Related]
7. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs.
Wu C; Dong N; da Cunha V; Martin-McNulty B; Tran K; Nagashima M; Wu Q; Morser J; Wang YX
Thromb Haemost; 2003 Sep; 90(3):414-21. PubMed ID: 12958609
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of tissue-type plasminogen activator transgenic rats.
Ito Y; Noguchi K; Morishima Y; Yamaguchi K
J Thromb Thrombolysis; 2018 Jan; 45(1):77-87. PubMed ID: 29168147
[TBL] [Abstract][Full Text] [Related]
9. Pre-administration of a carboxypeptidase inhibitor enhances tPA-induced thrombolysis in mouse microthrombi: Evidence from intravital imaging analysis.
Mathews NS; Suzuki Y; Honkura N; Sano H; Iwashita T; Urano T
Thromb Res; 2022 Feb; 210():78-86. PubMed ID: 35030422
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa).
Noguchi K; Edo N; Miyoshi N; Isobe A; Watanabe A; Ito Y; Morishima Y; Yamaguchi K
Thromb Res; 2018 Aug; 168():96-101. PubMed ID: 29957475
[TBL] [Abstract][Full Text] [Related]
11. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Wang X; Smith PL; Hsu MY; Ogletree ML; Schumacher WA
J Thromb Haemost; 2006 Feb; 4(2):403-10. PubMed ID: 16420573
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B.
Suzuki K; Muto Y; Fushihara K; Kanemoto K; Iida H; Sato E; Kikuchi C; Matsushima T; Kato E; Nomoto M; Yoshioka S; Ishii H
J Pharmacol Exp Ther; 2004 May; 309(2):607-15. PubMed ID: 14762098
[TBL] [Abstract][Full Text] [Related]
13. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro.
Walker JB; Hughes B; James I; Haddock P; Kluft C; Bajzar L
J Biol Chem; 2003 Mar; 278(11):8913-21. PubMed ID: 12643276
[TBL] [Abstract][Full Text] [Related]
14. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.
Ni R; Neves MAD; Wu C; Cerroni SE; Flick MJ; Ni H; Weitz JI; Gross PL; Kim PY
J Thromb Haemost; 2020 Sep; 18(9):2364-2376. PubMed ID: 32506822
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.
Foley JH; Cook PF; Nesheim ME
J Biol Chem; 2011 Jun; 286(22):19280-6. PubMed ID: 21467042
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
Mertens JC; Boisseau W; Leenaerts D; Di Meglio L; Loyau S; Lambeir AM; Ducroux C; Jandrot-Perrus M; Michel JB; Mazighi M; Hendriks D; Desilles JP
J Thromb Haemost; 2020 Dec; 18(12):3325-3335. PubMed ID: 32869423
[TBL] [Abstract][Full Text] [Related]
17. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.
Zhou J; Kochan J; Yin O; Warren V; Zamora C; Atiee G; Pav J; Orihashi Y; Vashi V; Dishy V
J Thromb Haemost; 2017 May; 15(5):961-971. PubMed ID: 28211169
[TBL] [Abstract][Full Text] [Related]
18. Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis.
Sasaki T; Yoshimoto N; Sugimoto K; Takada K; Murayama N; Yamazaki H; Yamamoto K; Ishii H
Thromb Res; 2012 Oct; 130(4):e222-8. PubMed ID: 22795218
[TBL] [Abstract][Full Text] [Related]
19. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
20. S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.
Sansilvestri-Morel P; Rupin A; Schaffner AP; Bertin F; Mennecier P; Lapret I; Declerck PJ; Baumy P; Vallez MO; Petit-Dop F; Tupinon-Mathieu I; Delerive P
Thromb Res; 2021 Aug; 204():81-87. PubMed ID: 34153648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
